膝关节镜结合中药熏洗治疗膝骨关节炎的临床效果

目的:探讨膝关节镜结合中药熏洗方案治疗膝骨关节炎(KOA)患者的临床效果。方法:收集2014年1月—2016年12月玉田县中医医院诊治的66例KOA患者,按照治疗方案不同分为两组,对照组(32例)行单纯中药熏洗治疗,观察组(34例)行关节镜清理术联合中药熏洗治疗,回顾观察并分析患者疼痛程度、关节症状、炎性因子水平、生活质量等变化情况。结果:观察组治疗后2、4周及3、6个月的视觉模拟评分法(VAS)评分均显著低于对照组(P<0.05);观察组治疗后膝骨性关节炎严重性指数ISOA)、国际膝骨性关节炎(WOMAC)量表评分低于对照组(P<0.05);观察组治疗后的白细胞介素-1(IL-1)、白细胞介素-6(IL-6)及超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)水平比对照组显著更低(P<0.05);观察组的总有效率为94.12%,显著高于对照组的76.47%,SF-36总评分显著高于对照组,差异均有统计学意义(P<0.05)。结论:联合给予KOA患者膝关节镜手术、中药熏洗治疗,可明显提高患者关节症状改善效果,减轻疼痛程度,提高抗炎效果,获得更理想临床总疗效及预后。     

Safety,pharmacokinetic and pharmacodynamic studies of batifiban injection following single- and multiple-dose administration to healthy Chinese subjects

Batifiban, a synthetic cyclic peptide, is a potent platelet glycoprotein GPⅡb/Ⅲa antagonist which may be useful in the treatment and prevention of acute coronary syndromes. The pharmacokinetics and pharmacodymanic （inhibition of platelet aggregation） effects, and tolerability of batifiban were investigated in healthy subjects following single bolus injection with doses of 55, 110, or 220 μg/kg, or multiple doses of an bolus followed intravenous infusion for 24 h （180 μg/kg plus 2.0 μg/minokg, and 220 μg/kg plus 2.5μg/minokg） in this phase I clinical trial. Plasma levels of batifiban and areas under the curve were found to be proportional to doses. Batifiban was rapidly eliminated with a half-life of approximately 2.5 h. Significant differences were noted for plasma levels of batifiban and areas under the curve between males and females. No significant differences in the terminal half-life were found between males and females. Batifiban reversibly inhibited ex vivo platelet aggregation in a dose- and concentration-dependent manner, consistent with its mechanism as a GPⅡ b/Ⅲa antagonist. Single and multiple intravenous doses of batifiban were found to be safe and well tolerated in healthy subjects. These results support a bolus injection plus intravenous infusion regimen of batifiban for the treatment and prevention of acute coronary syndromes.     

网络成瘾住院患者冲动、攻击性人格特点及治疗转归

目的 了解网络成瘾住院患者冲动、攻击性人格特点以及经过综合性网瘾戒治后转归情况.方法 采用Barratt冲动性量表(BIS)、Buss行为攻击问卷(BAS)、症状自评量表(SCL-90)分别对58例网络成瘾住院患者在入院1周内和综合性网瘾戒治3月后进行评估,并与54例正常对照比较.结果 ①IAD组治疗前冲动、攻击量表各因子分以及总分均比正常对照组高[BIS评分(99.3±15.1)分,(75.0±15.4)分,t=8.47,P＜0.01;BAS评分(78.3±24.4)分,(54.8±17.7)分,t=5.87,P＜0.01];治疗后冲动、攻击量表除躯体攻击外,其余各因子分以及总分明显降低但仍比正常对照高[BIS评分(86.3±16.6)分,(75.0±15.4)分,t=4.98,P＜0.01;BAS评分(66.2±22.6)分,(54.8±17.7)分,t=3.65,P＜0.01];②IAD组SCL-90总分与BAS量表总分存在显著相关性(r=0.376,P＜0.01),治疗后SCL-90总分降低值与BAS降低值亦存在相关(r=0.508,P＜0.01).结论 网络成瘾组冲动、攻击性比正常对照组高,经治疗后其冲动、攻击性降低,但仍高于对照组.

Abstract：

Objective To explore the impulsivity and aggressivity,and its treatment outcomes of the inpatients with intemet addiction disorder (IAD) by intergration interview. Methods Barratt Impulsiveness Scale ( BIS), Buss Aggressive Scale (BAS) were used to assess the impulsiveness and aggressivity in 58 IAD patients, at the first week and after the point of intergration interview 3 months,54 normal subjects in the control group were conducted by BIS and BAS only when they were recruited. Results ①The intemet addiction group had significantly higher scores on the BIS and BAS total scores than the control group at the first week ( BIS score 99.3 ±15. 1vs 75.0 ± 15.4, t=8.47, P＜0. 01; BAS score 78.3 ±24.4 vs 54.8 ± 17.7, t=5.87 , P＜0. 01 ). IAD group had lower scores on the total scores of BIS-Ⅱ and BAS after intergration interview than before, but the subscales and total scores were higher than those in the control group ( BIS score 86.3 ± 16.6 vs 75.0 ± 15.4, t =4.98, P ＜ 0.01 ;BAS score 66.2 ± 22.6 vs 54.8 ± 17.7, t = 3.65, P ＜ 0. 01 ). ②Total score of SCL-90 in IAD group were significantly correlated with the BAS total score ( r=0. 376, P＜0. 01 ) ,and the decreased SCL-90 total score was also related with the decreased BAS score ( r= 0.508, P＜ 0. 01 ). Conclusion This study suggests that IAD group exhibit more impulsivity and aggressivity than those in the control group. After interview, their impulsivity and aggressivity are significantly decreased, but are still higher than those in the normal control group.     

探究微创踝关节融合术治疗足踝创伤性关节炎的效果评价

目的探究微创踝关节融合术治疗足踝创伤性关节炎的效果。方法以我院接收患者为例,患者均选择自足踝创伤性关节炎患者中,本研究开展时间为2017年12月至2018年12月,本研究共选取人数100人,将其根据自身意愿分为两组,分别为微创组和开放组,每组有患者50例,分别给予其微创踝关节融合术治疗和常规开放性治疗,对其治疗效果进行观察比较。结果微创组患者和开放组患者在术后6个月的骨性融合率存在显著差异,分别为80.00%和30.00%,微创组效果更好,数据对比结果为P0.05,存在统计学意义。两组患者在术后1年的骨性融合率均得到100%。两组患者在术前和术后6个月的AOFAS评分不存在明显差异,其统计学结果为P 0.05,不存在统计学意义。而术后1年,微创组患者的AOFAS踝与足功能评分明显高于开放组评分,其数据差异对比存在统计学意义,P0.05。结论针对存在足踝创伤性关节炎患者,给予其微创踝关节融合术治疗的治疗效果更加显著,其能够有效改善患者足踝功能,值得临床提高对此技术方法的重视程度,进行积极推广。     

基于关节镜治疗运动创伤性踝关节炎的效果分析

目的探究分析基于关节镜治疗运动创伤性踝关节炎的效果。方法选取2017年1月22日到2018年10月15日我院收治的74例运动创伤性踝关节炎患者为研究对象,依据入院床位单双号将其分为对照组(n=37)和实验组(n=37),对照组人员采取常规手术治疗,实验组人员选择关节镜治疗。对两组患者临床疗效及并发症发生情况、临床指标进行比较。结果实验组患者临床治疗有效率97.30%明显高于对照组81.08%,差异显著(P0.05)。两组患者并发症发生率对比,差异无统计学意义(P 0.05)。实验组患者踝关节功能恢复及关节疼痛消失时间均优于对照组,差异显著(P0.05)。结论关节镜治疗运动创伤性踝关节炎效果较好,对患者恢复有积极影响。     

小分子靶向药物和生物制剂治疗斑秃的研究进展

【摘要】 斑秃的传统治疗方法疗效欠佳，尤其是对中重度斑秃和特殊类型斑秃。小分子靶向药物和生物制剂较传统疗法起效快、疗效显著，但部分患者治疗期间会出现感染等不良反应或停药后会复发，其有效性和安全性仍需进一步评估。本文综述小分子靶向药物和生物制剂在斑秃治疗中的研究进展。     

Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Parathyroid Hormone [rhPTH （1-84）] in Chinese Healthy Volunteers

The current study was designed to determine the safety, tolerability and pharmacokinetic parameters of recombinant human parathyroid hormone [rhPTH （1-84）] used for the treatment of osteoporosis. In the single-dose format pharmacokinetic study, thirty-six healthy male volunteers received three dose levels of rhPTH （1-84） subcutaneously： 1, 2, and 4 μg/kg. The blood was timing drawn and the serum concentration of rhPTH （1-84） was determined by enzyme linked immunosorbent assay （ELISA）. Serum concentration-time curves of PTH （1-84） exhibited a double-peak pattern, the first peak appearing about 10 to 30 min after administration and the second peak occurring about 1.5 to2 h after administration. Serum terminal half-time of PTH （1-84） was approximately 2 h. The parameters indicated the serum levels were directly proportional to the administered dose, with the mean Cmax and AUC0_24 ranging from approximately 543.47 to 1845 pg/mL and 2358.6 to 9232.12 pg.h.mL^-1 over the dose range. The drug was well tolerated, the clinical symptoms were generally mild and of short duration.     

鼻内镜手术治疗筛前动脉破裂致顽固性鼻出血5例

鼻出血是耳鼻咽喉科常见病、多发病,也是常见急症之一。可由鼻部局部疾病引起,也可是全身疾病的局部表现。出血量多少不一,少则为涕中带血,重者可致出血性休克[1]。本文就我科治疗的5例临床上比较少见的筛顶部的筛前动脉破裂导致的难治性鼻出血,报道如下。1资料与方法1.1临床资料2012年1月-8月我科收治难治性鼻出血患者5例,其中男4例,女1例;     

注射用鼠抗人T淋巴细胞CD25抗原单克隆抗体在健康受试者体内药代动力学与药效学

目的 研究注射用鼠抗人T淋巴细胞CD25抗原单克隆抗体(WuTac)单次给药在中国健康受试者体内的药代动力学特征和药效学效应.方法 36名健康受试者,男女各半,随机分配到高,中,低(0.20,0.10,0.05 mg·kg-1)3个剂量组,通过酶联免疫吸附(ELISA)检测受试者血清中WuTac和人抗鼠抗体(HAMA)的浓度,评估该药物的药代动力学行为特征.通过流式细胞仪检测全血中T淋巴细胞表面CD25结合位点,计算白介-2受体(IL-2R)饱和度,对本品的药效学做出评判.结果 高,中,低3个剂量组的主要药代动力学参数如下:t1/2分别为(54.15±16.50),(54.39 ±21.17),(43.99±13.07)h;tmax分别为(2.50±2.02),(2.75 ±2.01),(2.08±2.06)h;Cmax分别为(2950.82±560.94),(1461.20±370.70),(608.95±81.66)μg·L-1;AUC0-t分别为(8881.90±2188.10),(3711.00±1146.10),(1158.20±306.20)μg·L-1·d;AUC0-∞分别为(9458.80±2547.80),(4115.40±1208.40),(1269.70±310.40)μg·L-1·d.高,中,低3个剂量组单次恒速滴注停药1 h后,均能饱和T细胞白介2受体(IL-2R)相应结合位点,饱和度达96%以上,维持饱和3 d以上.结论 本品在中国健康人体起效迅速,疗效持久.单次给药耐受性良好,呈线性药代动力学特征.     

重症肌无力病人血清非免疫球蛋白成分中的14KD蛋白

在21例抗体阳性、20例抗体阴性重症肌无力(MG),18例其他神经科疾病(OND)患者和19例正常对照血清中制备非免疫球蛋白(Ig)成分。并予以聚丙烯酰胺凝胶电泳(SDS-PAGE)和等电聚焦(IEF)电泳分析。结果显示,大多数MG病人的非Ig成分电泳图谱中有一分子量为14KD的特异蛋白区带,其出现频度以抗体阴性MG(85％)最高,与抗体阳性MG(52.38％)比较差异有显著性(P<0.05)。14KD蛋白可能参与了MG的发病,尤其在抗体阴性MG中的作用可能更为重要。